2023-04-19 09:15:00 ET
British drugmaker AstraZeneca (NASDAQ: AZN) and U.S.-based Ionis Pharmaceuticals (NASDAQ: IONS) have been working jointly on a drug candidate for treating a rare disease known as transthyretin (ATTR) amyloidosis polyneuropathy. The potential medication, eplontersen, recently showed positive results in a phase 3 clinical trial.
What could this mean for AstraZeneca's sales if eplontersen is approved? Let's dig into the global ATTR amyloidosis market to find out.
Transthyretin (ATTR) amyloidosis is a rare condition that gets progressively worse. In amyloidosis, abnormal proteins known as amyloids accumulate in the peripheral nerves and organs within the body, which can lead to nerve damage.
For further details see:
Could This Rare-Disease Drug Candidate Become a Blockbuster?